SecBot SecBot

KALA drug pipeline

KALA BIO, Inc. · 2 rated drugs
$0.1390
−13.7% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseNot stated
Time to marketNot stated

KPI-014 Updated Nov 12

What to watch

KPI-014 is an early preclinical program at a company that recently suffered a clinical failure (KPI-012 Phase 2b miss in September 2025), has a market cap around $3M, and is pivoting to an AI platform business model. Watch for any mention of KPI-014 in future corporate updates, but the program appears dormant or deprioritized given the company's financial constraints and strategic shift.

Bull case
  • KPI-014 targets inherited retinal degenerative diseases (retinitis pigmentosa, Stargardt disease), areas with significant unmet need and no approved therapies for many patients.
  • The MSC-S platform is a novel biologic approach that could differentiate from gene therapy competitors if preclinical data prove promising.
  • KALA BIO has dramatically reduced its cash burn (Q3 2026 net loss of ~$0.8M vs $7.6M in Q3 2025), extending its runway to potentially advance early-stage programs.
Bear case
  • KPI-014 is preclinical only with no clinical trials initiated, no IND filed, and no hard catalyst in the next ~12 months.
  • KALA BIO's lead candidate KPI-012 failed its Phase 2b CHASE study in September 2025, causing an 88% stock crash and raising questions about the MSC-S platform's therapeutic potential.
  • The company is pivoting to an AI infrastructure platform business model, suggesting KPI-014 and the broader biologics pipeline may be deprioritized.
▼ bearish
Impact
PhasePhase 2b (failed)
Time to marketNot stated

KPI-012 Updated Nov 12

What to watch

KPI-012 development has been ceased after a Phase 2b failure. KALA BIO is pivoting to non-drug businesses (telehealth, genetic testing distribution, AI infrastructure). The next event is Q3 2026 earnings on November 17, 2026, but that will reflect the company's pivot, not KPI-012 progress. There are no further catalysts for this drug.

Bull case
  • KPI-012 was well-tolerated in the Phase 2b trial with no treatment-related serious adverse events observed, suggesting a favorable safety profile.
  • The drug had received FDA Fast Track Designation in April 2023 for PCED, a rare and debilitating eye condition with no approved therapies addressing all underlying etiologies.
  • KALA BIO has been pivoting to new business lines (telehealth acquisition LOI, Virotek genetic testing distribution, AI infrastructure) but these are unrelated to KPI-012.
Bear case
  • KPI-012 failed its Phase 2b CHASE trial in September 2025, missing the primary endpoint of complete healing of PCED at Week 8, with secondary endpoints also not reaching statistical significance.
  • KALA BIO announced it would cease development of KPI-012 after the failure, effectively ending the drug's clinical program.
  • The stock collapsed approximately 92% on the news, dropping from a 52-week high of $95.50 to around $0.18, reflecting near-total loss of value tied to this asset.